Nomura Maintains Buy Rating on Dr Reddy's

Nomura has reiterated its Buy recommendation on Dr Reddy's Laboratories with a target price of ₹1,600 following the company's launch of generic Bosulif (Bosutinib Tablets 400 mg) in the United States.

The brokerage considers the launch a positive development because it was not widely anticipated by the market and introduces a new earnings opportunity in the highly lucrative U.S. generic pharmaceutical market.

The product launch also highlights Dr Reddy's ability to capitalize on complex generic opportunities through strategic partnerships.

What Makes This Launch Important?

Dr Reddy's has launched generic Bosulif with 180 days of market exclusivity in the United States.

Exclusivity periods are particularly valuable because competition remains limited during the initial launch phase, allowing generic manufacturers to capture a larger portion of market demand before multiple competitors enter.

According to Nomura, the branded product generates annual sales of approximately USD 214 million, making it a meaningful opportunity for the company.

Key Details of the Opportunity

Why Was the Market Surprised?

Nomura notes that the partnership with MSN Laboratories had not been publicly disclosed earlier, making the launch an unexpected positive development.

MSN is believed to be the sole first ANDA filer for the product, providing a competitive advantage during the exclusivity period.

Unexpected launches often attract investor attention because they can improve earnings forecasts without being previously factored into market expectations.

Nomura's Revenue Expectations

The brokerage assumes a price erosion of approximately 30% to 40% during the exclusivity period and expects the product to capture around 40% market share.

Based on these assumptions, Nomura estimates that the launch could contribute approximately USD 25 million to USD 30 million in revenue during FY26.

For a mature pharmaceutical company, such contributions from a single launch can provide a meaningful boost to earnings momentum.

Key Positives Investors May Watch

✅ 180-day exclusivity advantage.

✅ Access to a USD 214 million market opportunity.

✅ Positive surprise launch.

✅ Growing oncology product exposure.

✅ Potential FY26 revenue contribution.

✅ Strengthening U.S. generics portfolio.

Investor Takeaway

Nomura believes the Bosulif launch represents a meaningful positive surprise for Dr Reddy's Laboratories. The combination of 180-day exclusivity, partnership with MSN Laboratories and exposure to a sizeable U.S. market creates a potentially attractive earnings opportunity. While generic drug launches often face pricing pressure over time, the initial exclusivity period could provide a valuable revenue boost and reinforce investor confidence in the company's U.S. growth strategy. Read more market insights at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.